Clinical Trial

Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma

Name: Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma — clinical trial record (NCT07123545)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The goal of this open-label, single-arm phase I/II clinical trial is to evaluate the feasibility, safety, and anti-tumor efficacy of the autologous neoantigen-specific T-cell therapy (iNeo-Vac-T01) in patients with advanced hepatocellular carcinoma who have failed second-line or later systemic therapies.

Trial Details

NCT Number	NCT07123545
Lead Sponsor	Zhejiang University Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions	Advanced Hepatocellular Carcinoma (HCC)
Enrollment	20 participants
Start Date	2025-08-01
Primary Completion	2027-07-31 (estimated)
Study Completion	2029-07-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-14